blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1103272

EP1103272 - Modulation of TGF-beta by proteolytic enzymes [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  25.08.2006
Database last updated on 06.07.2024
Most recent event   Tooltip25.08.2006Application deemed to be withdrawnpublished on 27.09.2006  [2006/39]
Applicant(s)For all designated states
MUCOS Pharma GmbH & Co.
Malvenweg 2
82538 Geretsried / DE
[N/P]
Former [2001/22]For all designated states
MUCOS Pharma GmbH & Co.
Malvenweg 2
D-82538 Geretsried / DE
Inventor(s)01 / Ransberger, Karl
Seepromenade 5
82402 Seeshaupt / DE
02 / Stauder, Gerhard
Primelweg 2
82538 Geretsried / DE
03 / Desser, Lucia
Volkgasse 6
1130 Wien / AT
 [2001/22]
Representative(s)Grünecker Patent- und Rechtsanwälte PartG mbB
Leopoldstrasse 4
80802 München / DE
[N/P]
Former [2001/22]Grünecker, Kinkeldey, Stockmair & Schwanhäusser Anwaltssozietät
Maximilianstrasse 58
80538 München / DE
Application number, filing date00126088.429.11.2000
[2001/22]
Priority number, dateDE199915731829.11.1999         Original published format: DE 19957318
[2001/22]
Filing languageDE
Procedural languageDE
PublicationType: A2 Application without search report 
No.:EP1103272
Date:30.05.2001
Language:DE
[2001/22]
Type: A3 Search report 
No.:EP1103272
Date:26.02.2003
[2003/09]
Search report(s)(Supplementary) European search report - dispatched on:EP14.01.2003
ClassificationIPC:A61K38/48, A61P17/00, A61P19/00, A61P9/10, A61P35/00, A61P37/00, A61P13/12, A61P39/02, // (A61K38/48, 31:7048)
[2001/22]
CPC:
A61K38/4826 (EP); A61P13/12 (EP); A61P17/00 (EP);
A61P19/00 (EP); A61P35/00 (EP); A61P37/00 (EP);
A61P37/04 (EP); A61P39/02 (EP); A61P9/10 (EP) (-)
Designated contracting statesAT,   BE,   CH,   CY,   DE,   DK,   ES,   FI,   FR,   GB,   GR,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   SE,   TR [2001/22]
TitleGerman:Beeinflussung von TGF-Beta durch proteolytische Enzyme[2001/22]
English:Modulation of TGF-beta by proteolytic enzymes[2001/22]
French:Modulation du TGF-beta par des enzymes protéolytiques[2001/22]
Examination procedure16.07.2003Examination requested  [2003/38]
23.09.2005Despatch of a communication from the examining division (Time limit: M06)
04.04.2006Application deemed to be withdrawn, date of legal effect  [2006/39]
09.05.2006Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time  [2006/39]
Fees paidRenewal fee
28.11.2002Renewal fee patent year 03
28.11.2003Renewal fee patent year 04
26.11.2004Renewal fee patent year 05
29.11.2005Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[X]DE4302060  (MUCOS PHARMA GMBH & CO [DE]) [X] 1-8 * column 1; claims 1-10 *;
 [X]WO9600082  (CORTECS LTD [GB], et al) [X] 1-4,6-8,11 * claims 1,14-18 *;
 [X]WO9724138  (CORTECS LTD [GB], et al) [X] 1-4,6-8,11 * claims 1,13-17 *;
 [X]DE19726244  (MUCOS PHARMA GMBH & CO [DE]) [X] 1-8,11 * claims 1-7 *;
 [X]EP0943337  (MUCOS PHARMA GMBH & CO [DE]) [X] 1-8 * claims 1-7 *;
 [X]  - GACIONG Z ET AL, "Protease therapy alleviates allograft arteriosclerosis in rats", TRANSPLANTATION PROCEEDINGS, ORLANDO, FL, US, (19961201), vol. 28, no. 6, ISSN 0041-1345, pages 3439 - 3440, XP002082012 [X] 1-4,6-8,11 * abstract * * page 3440, column 1, paragraph 2 *
 [X]  - STAUDER ET AL, "Strahlentherapeutische Nebenwirkungen bei Abdominalkrebspatienten und deren Reduktion durch hydrolytische Enzympräparate", DTSCH.ZSCHR.ONKOL., (1991), vol. 23, no. 1, pages 7 - 16, XP001121080 [X] 1-4,8,10 * abstract * * Diskussion *
 [X]  - SCHEDLER ET AL, "Adjuvant therapy with hydrolytic enzymes in oncology a hopeful effort to avoid bleomycin induced pneumotoxicity", J. CANCER RESEARCH AND CLINICAL ONCOLOGY, (1990), vol. 116, no. Supp.1, page 697, XP009002920 [X] 1,8,9 * abstract *
 [X]  - PACZEK ET AL, "Beneficial effect of proteases on TGF-beta production in glomeruli from streptozotocin induced diabetes mellitus in rats", INT.J.TISS.REAC., (1997), vol. XIX, no. (1/2), pages 93 - 94, XP009002930 [X] 1-8,12-15 * abstract *
 [XY]  - DESSER L ET AL, "Polyenzyme preparations interrupt the autocrine loop of TGF-beta production in melanoma cells by conversing alpha2Macroglobulin (a2M) into the fast-form which binds TGF-beta irreversible", EUROPEAN JOURNAL OF CANCER, PERGAMON PRESS, OXFORD, GB, (199909), vol. 35, ISSN 0959-8049, page S375, XP004385434 [X] 1-8,14,15 * abstract * [Y] 1-8

DOI:   http://dx.doi.org/10.1016/S0959-8049(99)81940-6
 [Y]  - BIENKOWSKI, GOTKIN, "Control of collagen Deposition in Mammalian Lung", PROC.SOC.EXP.BIOL.MED., (1995), vol. 209, pages 118 - 142, XP009002944 [Y] 1-8 * page 125, column 2, paragraph 3 - page 126, column 1, paragraph 1 * * abstract *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.